News & Updates
Filter by Specialty:
Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.
Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
07 Sep 2022
Topical combination, physical treatments best for mild-to-moderate acne
Topical pharmacological treatment combinations, chemical peels, and photochemical therapy are deemed to be the best and the most effective options for mild-to-moderate acne vulgaris.
Topical combination, physical treatments best for mild-to-moderate acne
06 Sep 2022
Levonorgestrel-releasing intrauterine system reduces pelvic pain but may increase expulsion risk
In the treatment of patients with organic disease and heavy menstrual bleeding and/or dysmenorrhea, the use of levonorgestrel-releasing intrauterine system (LNG-IUS) attenuates chronic pelvic pain, according to a study. However, it appears to confer an increased risk of expulsion for some women.
